Erwin G Van Meir

List of Publications by Year
in descending order

76	12,034	76196 40	85405 71
papers	citations	h-index	g-index

77	77	77	18583
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
2	Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. Ca-A Cancer Journal for Clinicians, 2010, 60, 166-193.	157.7	1,182
3	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	7.7	836
4	The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology, 2005, 7, 122-133.	0.6	610
5	Frequent Coâ€Alterations of TP53, p16/CDKN2A, p14^{ARF}, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.. Brain Pathology, 1999, 9, 469-479.	2.1	497
6	Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. International Journal of Biochemistry and Cell Biology, 2004, 36, 1046-1069.	1.2	449
7	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Research, 2015, 25, 316-327.	2.4	343
8	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
9	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266
10	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Molecular Cell, 2014, 53, 534-548.	4.5	247
11	Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene, 2005, 24, 3632-3642.	2.6	159
12	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. , 1998, 79, 640-644.		153
13	Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1)in vivo andin vitro. International Journal of Cancer, 1994, 58, 240-247.	2.3	141
14	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene, 2000, 19, 3816-3822.	2.6	129
15	Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Medicinal Chemistry, 2013, 5, 553-572.	1.1	116
16	Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene, 1999, 18, 1447-1456.	2.6	110
17	Hypoxia inducible factor-1: a novel target for cancer therapy. Anti-Cancer Drugs, 2005, 16, 901-909.	0.7	110
18	Identification of a Novel Small Molecule HIF-1Î± Translation Inhibitor. Clinical Cancer Research, 2009, 15, 6128-6136.	3.2	102

#	Article	IF	Citations
19	Vasculostatin Inhibits Intracranial Glioma Growth and Negatively RegulatesIn vivoAngiogenesis through a CD36-Dependent Mechanism. Cancer Research, 2009, 69, 1212-1220.	0.4	99
20	Brain Angiogenesis Inhibitor 1 Is Differentially Expressed in Normal Brain and Glioblastoma Independently of p53 Expression. American Journal of Pathology, 2003, 162, 19-27.	1.9	90
21	Human Brat Ortholog TRIM3 Is a Tumor Suppressor That Regulates Asymmetric Cell Division in Glioblastoma. Cancer Research, 2014, 74, 4536-4548.	0.4	90
22	Cytokines and tumors of the central nervous system. Glia, 1995, 15, 264-288.	2.5	89
23	Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation. Advances in Anatomic Pathology, 2002, 9, 24-36.	2.4	88
24	Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model. Cancer Research, 2006, 66, 11991-11997.	0.4	81
25	Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research, 2015, 28, 135-147.	1.5	81
26	Tumor initiating cells in malignant gliomas: biology and implications for therapy. Journal of Molecular Medicine, 2009, 87, 363-374.	1.7	80
27	Detection of â€œoncometaboliteâ€•2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. Journal of Molecular Medicine, 2012, 90, 1161-1171.	1.7	77
28	Arylsulfonamide KCN1 InhibitsIn VivoGlioma Growth and Interferes with HIF Signaling by Disrupting HIF-1Î± Interaction with Cofactors p300/CBP. Clinical Cancer Research, 2012, 18, 6623-6633.	3.2	74
29	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene, 1999, 18, 5870-5878.	2.6	72
30	Overexpression of MBD2 in Glioblastoma Maintains Epigenetic Silencing and Inhibits the Antiangiogenic Function of the Tumor Suppressor Gene BAI1. Cancer Research, 2011, 71, 5859-5870.	0.4	68
31	p53 and Brain Tumors: From Gene Mutations to Gene Therapy. Brain Pathology, 1998, 8, 599-613.	2.1	64
32	Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas. Oncogene, 2001, 20, 1103-1109.	2.6	63
33	Adhesion GPCRs in Tumorigenesis. Handbook of Experimental Pharmacology, 2016, 234, 369-396.	0.9	63
34	Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors. Clinical Cancer Research, 2004, 10, 8603-8612.	3.2	62
35	Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. Journal of Molecular Medicine, 2011, 89, 743-752.	1.7	59
36	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell, 2018, 33, 1004-1016.e5.	7.7	52

#	Article	IF	Citations
37	New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene, 1997, 15, 997-1000.	2.6	50
38	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47
39	Absence ofp53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. , 1998, 76, 797-800.		46
40	Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. Journal of Cellular Biochemistry, 2001, 82, 619-633.	1.2	45
41	Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma. Clinical Cancer Research, 2019, 25, 2206-2218.	3.2	45
42	Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway. Journal of Medicinal Chemistry, 2011, 54, 8471-8489.	2.9	44
43	Engineering Human Tumor-specific Cytotoxic T Cells to Function in a Hypoxic Environment. Molecular Therapy, 2008, 16, 599-606.	3.7	43
44	Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. Clinical Cancer Research, 2016, 22, 6256-6265.	3.2	43
45	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clinical Cancer Research, 2018, 24, 6471-6482.	3.2	42
46	A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresis. Scientific Reports, 2019, 9, 4437.	1.6	38
47	Structureâ€“activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. Bioorganic and Medicinal Chemistry, 2012, 20, 4590-4597.	1.4	35
48	Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene, 1998, 16, 321-326.	2.6	34
49	EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. Oncogene, 2020, 39, 1041-1048.	2.6	33
50	Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5528-5532.	1.0	32
51	A role for activated Cdc42 in glioblastoma multiforme invasion. Oncotarget, 2016, 7, 56958-56975.	0.8	32
52	KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology. PLoS ONE, 2012, 7, e44883.	1.1	29
53	BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infectionâ€”Implications for Oncolytic Viral Therapy. Clinical Cancer Research, 2017, 23, 1809-1819.	3.2	29
54	SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget, 2014, 5, 9703-9709.	0.8	27

#	Article	IF	Citations
55	Two new species of betatorqueviruses identified in a human melanoma that metastasized to the brain. Oncotarget, 2017, 8, 105800-105808.	0.8	27
56	Genomic Alterations in Human Malignant Glioma Cells Associate with the Cell Resistance to the Combination Treatment with Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand and Chemotherapy. Clinical Cancer Research, 2006, 12, 2716-2729.	3.2	26
57	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	3.3	24
58	Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Journal of Neuro-Oncology, 1995, 26, 191-198.	1.4	22
59	p53 and the CNS. Molecular Neurobiology, 1999, 19, 61-77.	1.9	22
60	At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. Journal of Molecular Medicine, 2011, 89, 91-94.	1.7	17
61	Neutrophils traffic in cancer nanodrugs. Nature Nanotechnology, 2017, 12, 616-618.	15.6	17
62	The expanding functional roles and signaling mechanisms of adhesion G proteinâ€"coupled receptors. Annals of the New York Academy of Sciences, 2019, 1456, 5-25.	1.8	16
63	Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Medicinal Chemistry Letters, 2012, 3, 620-625.	1.3	15
64	Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. International Journal of Cancer, 2001, 94, 35-43.	2.3	13
65	Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene, 2021, 40, 5182-5191.	2.6	13
66	Identification of nude mice in tumorigenicity assays. , 1997, 71, 310-310.		11
67	Mice lacking full length Adgrb1 (Bai1) exhibit social deficits, increased seizure susceptibility, and altered brain development. Experimental Neurology, 2022, 351, 113994.	2.0	9
68	A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget, 2017, 8, 99245-99260.	0.8	8
69	Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 992-1001.	2.5	7
70	A Chimeric Signal Peptideâ€"Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cellâ€"Specific Apoptosis. Clinical Cancer Research, 2020, 26, 2711-2724.	3.2	7
71	Ten-eleven translocation protein 1 modulates medulloblastoma progression. Genome Biology, 2021, 22, 125.	3.8	3
72	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. , 1998, 79, 640.		3

#	Article	IF	Citations
73	BAI1: from cancer to neurological disease. Oncotarget, 2016, 7, 17288-17289.	0.8	3
74	Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio-protocol, 2017, 7, .	0.2	2
75	The advent of precision epigenetics for medulloblastoma. Oncoscience, 2020, 7, 47-48.	0.9	1
76	CBMS-7 IGF1/N-cadherin/Clusterin signaling axis mediates adaptive radioresistance of glioma stem cells. Neuro-Oncology Advances, 2021, 3, vi3-vi3.	0.4	0